plete and differential blood cell count; biochemistry test, particularly the LDH level; chest x-ray; chest, abdomen and pelvis CT scans; and bilateral bone marrow biopsies. Some special procedures such as lumbar puncture, brain CT or percutaneous liver biopsy were performed only if there was clinical suspicion of local involvement. Each patient was characterized using the following remission criteria after treatment: complete remission (CR), defined as a complete absence of any clinical or laboratory (biochemical or radiological) signs of disease maintained for at least four sequential weeks; partial remission (PR), defined as a reduction in tumor burden of 50% or more, measurable in two dimensions at the same time; refractory disease (RD), defined as a reduction in tumor burden of less than 50% compared with the original size, or a complete failure of response to treatment, or evidence of growing tumor burden during two sequential therapy cycles. The disease free-survival (DFS) was taken as the length of time between CR and the last consultation or the relapse. The overall survival (OS) used the same criteria for all patient situations.
The following clinical variables were evaluated: age in years; sex; race; general condition (performance status) in accordance with the Eastern Cooperative Oncology Group (ECOG); 8 extranodal site involvement; presence of bulk disease defined as a tumor burden mass larger than 10 cm in one diameter or occupying more than one third of the mediastinum; and CNS involvement. The LDH level was scored at three levels: ≤ 225 U/dl; > 225 and < 450 U/dl; and ≥ 450 U/dl. Biopsies from different disease sites, mostly lymphoid nodes, were reviewed in the Pathology Department and reclassified according to the WF. When there were plenty of samples, immunohistological studies were done on the B (CD-20) and T (CD45RO) markers using the ABC method. 9 The clinical stages were determined in accordance with the Ann Arbor classification. Seven different, non-randomized chemotherapy regimens were used. These were chosen based on the initial WF histological classification. The second and third generation schemes such as Macop-B, 7 PromaceCYTAbom 8 and the BFM-83 high-risk protocol 9 were used for high grade groups. CHOP, 10 BACOP 10 and MVPP 11 were used for intermediate groups. For low grade lymphoma, COP 11 and MVPP 11 were the most often used protocols.
Statistical Methods. Survival curves were plotted according to the method of Kaplan and Meier. 12 Statistical significance among curves was determined by the Cox-Mantel method, measuring variables with two categories of results, and the generalized Wilcoxon test leaving the 113 patients that constituted our first study. A second analysis was carried out on 93 patients who completed their follow-up and could be evaluated as regards their treatment.
The staging of the disease were done before and after treatment. The tests performed included: com- for those variables with more than two categories of results.
RESULTS
Patients' parameters in relation to the grade of lymphoma are shown in Tables 1 to 3 and the distribution of the 93 treated patients among the different chemotherapy schemes is shown in Table 4 .
The remission rates for high-grade lymphomas were: 62% CR, 25% PR and 12% RD; for the intermediate group: 50% CR, 27% PR and 23% RD; and for the low grade group: 44% CR, 32% PR and 24% RD. MACOP-B and CHOP were the treatments analyzed for high grade lymphoma and their CR were 66% and 40% respectively (P = 0.777). For the intermediate grade, the NCC = malignant lymphoma small non-cleaved cell; SCC = malignant lymphoma diffuse small cleaved cell; DMSLC = malignant lymphoma diffuse mixed small and large cell; DLC = malignant lymphoma diffuse large cell; FMSCLC = malignant lymphoma follicular mixed small cleaved and large cell; BM = bone marrow rate of CR to the protocols analyzed were: CHOP 61%, BACOP 41% and MACOP-B 50% (P = 0.1642). The median 5-year survival rates were: OS 62% and DFS 52% for high grade lymphoma, 57% and 49% for intermediate grade and 63% and 52% for low grade lymphoma respectively.
DISCUSSION
We analyzed patients with NHL divided into three subgroups in accordance with the WF classification and evaluated the variables that could demonstrate prognostic value. A second statistical study was done to check the influence of treatment on the survival for each variable studied at the first step.
The intermediate grade lymphomas presented results comparable to those described in the literature, probably because this was the largest group of patients. In this group the variables associated with worse prognosis were: B symptoms (P< 0.01); performance status III and IV (P< 0.01) and CNS involvement (P = 0.006). There are reports that patients with a diagnosis of performance status of III and IV is related to high cell proliferation and this fact could have implications of an unfavorable prognosis.
14 It is well known that better therapeutic results are associated with longer survival in patients that have a good performance status at the diagnosis. [5] [6] [7] 13 Involvement of the CNS generally implies frequently relapsing disease. 15 Some studies have suggested that patients with bone marrow involvement have a higher risk of presenting CNS infiltration. 15 This aspect was observed in our study.
The small number of patients with high and low grade lymphomas made it impossible to demonstrate statistically some important variables reported elsewhere such as: bone marrow and CNS involvement, bulk disease, mediastinal disease, high levels of LDH and age above 60 years. 15 For high grade lymphomas the following variables were related to worse disease: yellow race (P = 0.003), ECOG III and IV (P < 0.01) and extranodal disease (P < 0.01). After including the treatment, the only variable associated with an unfavorable prognosis for survival was CNS infiltration (P < 0.01). Many reports have demonstrated that extranodal disease, especially if there are two or more involved sites, is associated with worse evolution. 3, 16 This is valid for all kinds of lymphomas. This fact, even if negated by others, makes us think that it may be necessary to have other factors associated with the extranodal disease in order to cause a worse prognosis. 5, 6 For low grade lymphomas, only the lymphoplasmocytoid subset (P = 0.018) had prognostic value, and in the second study no variable was associated with treatment and survival.
The overall survival and DFS for all grades of the WF classification are quite similar to those of other studies, although our patients were treated with different non-randomized protocols. Costa et al. 7 had an OS of 54% and a 5-year DFS of 52% in a series of 54 high and intermediate grade lymphomas, most of which with diffuse histological patterns and advanced stage disease. Klimo & Connors 17 found a median 8-year survival of 62% and a DFS of 52% in 126 patients with diffuse large cell lymphoma. For the low-grade lymphoma, the OS and DFS were comparable to the many other studies that included patients with advanced stage disease. 3 A relationship between a high level of LDH and a worse survival for NHL has very often been reported. 5, 14, 18 Schneider et al. 21 pointed out the importance of this marker even when not considering the extent of the tumor nor the bulk mass burden. In our intermediate group, an LDH higher than 450U/dl had some relation with survival, with a p-value close to significance (P = 0.055).
Bone marrow involvement was not related to unfavorable survival in the three studied groups. We analyzed the presence or absence of focal or diffuse infiltration. For the intermediate grade lymphomas, there was a tendency towards diffuse marrow involvement and worse survival (P = 0.086). Data from the National Cancer Institute, Bethesda, USA, has postulated that marrow involvement means a poor prognostic factor for survival. A similar analysis performed at the M.D. Anderson Hospital was not able to predict this variable as an unfavorable factor. However, the association of bone marrow involvement, high LDH level and a high rate of cellular proliferation seems to have some prognostic meaning. 14 In both of our statistical analyses immunological phenotyping did not influence the survival of the three different groups. Our treatment was based on the first histological WF classification, but 43 of the 113 evaluated patients from the first study had their histological subtype changed after review. Thus, the philosophy of basing treatment on the initial diagnosis generated a miscellany of analyses. Despite having a small sample size, especially when analyzing each chemotherapy scheme in isolation, our data are similar to those in other reports. 8, 20 Although MACOP-B seems to be better than CHOP for CR rates, we can conclude that they are similar when considering OS and DFS. This conclusion has been confirmed by other reports in the last five years. 21 For the largest group, the intermediate lymphomas, there were no differences between CHOP, BACOP and MACOP-B relating to survival (P = 0.1642). When considered separately, CHOP showed a better rate of CR, 8/13 (61.50%), but this was not significant. At present, there is a world trend to use CHOP as the treatment schedule for aggressive lymphoma due to results that are similar and comparable to more toxic third-generation protocols. 7, 8, 13 For low-grade lymphomas our results are slightly inferior to those of other reports, but are comparable to studies that included advanced stage disease. 22 Even though 28% of those patients were treated with third-generation schemes and the others with CHOP, BACOP, MVPP or COP, no chemotherapy scheme was seen to be superior in relation to the prognosis (P = 0.2717). New treatment forms are being used for lowgrade lymphomas, especially purine analogs, interferon and allogeneic and autologous bone marrow transplantation. However their efficacy is still limited when compared with classic treatments such as usage of alkylating agents or aggressive chemotherapy. 23, 24 We believe that new studies and protocols are necessary in order to have a more precise conclusion about the best treatment for low grade lymphomas. 25 A new attempt at classifying NHL has recently been made. In this new classification, lymphoproliferative disorders are divided into B, T or NK diseases. 26 The cytogenetic characteristics and oncogenesis with their respective molecular rearrangements are considered in trying to describe each known pathology as an isolated entity. It is designated the REAL classification, signifying a consensus between American, European and Asian hemato-pathologists. This classification appears to have achieved the ideal, but more time and experience will be required before reaching a definitive conclusion on such a complex subject.
It is clear that we need to bring together clinical hematologists, pathologists and cytogeneticists in Brazil, in order attain a better understanding of the complex setting of this disease. Cooperation between institutions in different areas of the country could achieve clinical and therapeutic results. Only in this way will there be a commonality of spirit leading to a better understanding of NHL in Brazil.
r e s u m o CONTEXTO: Na doença de Hodgkin, cada estágio clínico ou patológico pode ser relacionado com a extensão da área envolvida e predizer a próxima região anatômica de risco para disseminação.
OBJETIVO:
Estabelecer os fatores prognósticos que melhor predizem sobrevida em LNH. 
TIPO DE ESTUDO:

